Skip to search formSkip to main contentSkip to account menu

Casodex

Known as: AstraZeneca brand of bicalutamide, Zeneca brand of bicalutamide, Astra brand of bicalutamide 
National Institutes of Health

Related topics

Related topics

2 relations
ICI-176334

Broader (1)

bicalutamide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens…
FOXP1 is a member of the winged helix or forkhead transcription factors. Recent studies have indicated possible roles for FOXP1… 
Highly Cited
2007
Highly Cited
2007
Androgen receptor or estrogen receptor‐β blockade alters DHEA‐, DHT‐, and E2‐induced proliferation and PSA production in human prostate cancer cells
Dehydroepiandrosterone (DHEA) is an endogenous steroid that is metabolized to androgens and/or estrogens in the human prostate… 
Review
2006
Review
2006
Combinatorial androgen receptor targeted therapy for prostate cancer.
Prostatic carcinogenesis is associated with changes in the androgen receptor (AR) axis converting it from a paracrine dependence… 
Highly Cited
1997
Highly Cited
1997
Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal…
OBJECTIVE We recently found amplification of the androgen receptor (AR) gene in approximately 30% of locally recurrent prostate… 
1997
1997
Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display
Review
1996
Review
1996
The development of Casodex (bicalutamide): preclinical studies.
Casodex (bicalutamide, Zeneca Limited) was developed for the treatment of prostate cancer from a series of nonsteroidal compounds… 
1994
1994
Current clinical studies with a new nonsteroidal antiandrogen, casodex
The efficacy of Casodex® (ICI 176,334; Zeneca Pharmaceuticals, Macclesfield, UK), a nonsteroidal antiandrogen, in the treatment… 
Highly Cited
1993
Highly Cited
1993
Metabolism and enantioselective pharmacokinetics of Casodex in man.
1. Five healthy male volunteers received a single oral dose (50 mg; 42 microCi) of 14C-Casodex, a racemic compound, which has its… 
Highly Cited
1992
Highly Cited
1992
Stable transfection of androgen receptor and MMTV-CAT into mammalian cells: Inhibition of cat expression by anti-androgens
Review
1989
Review
1989
"Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
The relative merits of the steroidal anti-androgen, cyproterone acetate, and the non-steroidal anti-androgens flutamide and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)